Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to dissemintate knowledge & skills of Acute Cardiovascular Care
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission: To promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our goal is to reduce the burden in cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our Mission is "to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death"
To improve quality of life and logevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
Working Groups goals is to stimulate and disseminate scientific knowledge in different fields of cardiology.
ESC Councils goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Prof. Salvatore Novo,
Results from our study on 150 patients together with findings from Framingham Heart and TNT suggest a possible “synergistic” role of low HDL-C and inflammation on the atherosclerotic disease progression from subclinical lesions to clinical events. It is possible to assert that the presence of subclinical carotid atherosclerosis together with low HDL-cholesterol concentrations points to a category of subjects at “high” CV risk.
The priority of primary cerebrovascular and cardiovascular disease prevention, must be placed on the identification of asymptomatic subjects at high risk of future events. “Global cardiovascular risk” (GCVR) is able to stratify the probable incidence of events through the evaluation of several traditional and emerging risk factors. The awareness of the role that dyslipidemia plays in the determinism of this risk has greatly influenced the management of subjects both in primary and secondary prevention.
Overwhelming evidence supports the causal relationship between elevated levels of low VA-HIT (LDL-C) and an increased risk of coronary artery disease (CAD), - CAD being the leading cause of death and morbidity worldwide. Benefits, as a consequence, arise from pharmacological treatments aimed at reducing LDL-C plasma levels (in addition to healthy diet and lifestyle). The AHA’s guidelines state that this treatment has, in general, a crucial role in reducing the risk of heart attacks and CV events in patients with CAD.
Statins are the preferred first-line pharmacological agents for their long, well-regarded history of efficacy and safety. Recent evidence indicate that lipid lowering strategies should be implemented at an early age, particularly in populations at high risk for CVD. Several agents have been evaluated in children, nevertheless as it is the case in adults, statins are the preferred drugs in paediatric practice. However, it is appropriate to raise a note of caution because this kind of therapy, initiated in childhood, needs to be studied in order to confirm its lifelong benefit (1).
Earlier scientific evidence on the effectiveness of statins has come from the WOSCOPS (West of Scotland Coronary Prevention Study) and from 4S (Scandinavian Simvastatin Survival Study).
Both studies showed a significant reduction not only in the LDL-C plasma levels (of about 26% and 35% respectively), but also in the relative risk of fatal and non-fatal myocardial infarction (of about 31% and 34%).
Although treatment goals are clearly defined, many patients do not reach their recommended LDL-C goals by simply using “starting doses” of statins. For such patients at high GCVR, a moreintensive therapy (ie with high-dose statins) is warranted. There is also the possibility of an intensive lipid-lowering treatment - by associating Ezetimibe to statins- which enhances the effect of statin but does not, in the meantime increase adverse complications (especially myopathy) (4). For potency in lowering LDL-C, favourable tolerability and patient acceptance/adherence profile, Ezetimibe/statin combination regimens arguably provide the maximum likelihood for subjects to reach new, lower LDL-C targets. A recent meta-analysis in patients with acute or chronic ischemic heart disease confirms the benefits arising from more aggressive lipid-lowering targets: “lower is better” (5). It is interesting to note however that an approach aimed only at reducing LDL-C has begun to show its limitations. Indeed a significant subject cohort in spite of a good control of the LDL-C remains at high risk (6). New strategies to reduce “residual” CV risk have paid attention to “levels” and “qualities” of HDL cholesterol (HDL-C).
Low HDL-C plasma levels can be considered an “independent” and “negative” prognostic factor in CV outcome. Its therapeutical modulation reduces CV risk, however optimal target levels have not yet been clearly defined. Statins are able to slightly increase HDL-C concentrations. High levels of HDL-C have anti-atherosclerotic properties, although the biological basis for this effect is not entirely clear. The "reverse cholesterol transport" model (plaque? macrophages? liver? biliary excretion) is currently the most widely used explanation for the protective role of HDL against the atherosclerotic disease. High-density lipoproteins, however, not only provide for a "forced" cholesterol flow from peripheral tissues to the liver, but are also involved in the control of cellular cholesterol homeostasis. Many other mechanisms are potentially involved, ie: preservation of endothelial function (7), anti-inflammatory activity and antioxidant effects, especially in terms of LDL. The oxidation of LDL causes a significant increase in the atherogenic potential of this class of lipoproteins.
Ample evidence supports the causal relationship of reduced levels of HDL-C (< 35/40 mg /dl) and the development of atherosclerotic diseases.
In light of the above considerations, it is possible to assert that low HDL-C concentrations can be considered a negative factor in CV outcome and are associated with an increased CV risk (11).
International guidelines agree to recommend HDL-C therapeutical modulation (11, 12). In spite of these assessments optimal levels of treatment goals have not been clearly defined, pharmacological drugs available are limited (with poor data regarding their use and effectiveness). Statins are only able to slightly increase HDL concentrations.
Another item to be taken into consideration has a “quality factor”, supposing a protective role for HDL “big” and “rich in cholesterol and ApoA-I” (which is the main enzyme involved in antioxidant effects).
Although it is well known that low HDL-cholesterol concentrations are associated with the development of atherosclerosis, recent evidence suggests that low HDL may further aggravate the atherosclerotic process. Lower HDL-C levels may potentially accelerate the progression from subclinical lesions (intima-media thickness=IMT; asymptomatic atherosclerotic carotid plaque=ACP) to clinical events. This effect could be due to the up-regulation of the inflammatory pathway: HDL-C seems to promote inflammation in the acute phase. Inflammation has been shown to be crucial in the evolution from endothelial dysfunction to plaque rupture and thrombosis.
IMT is the distance (assessed by B-mode ultrasonography) between two echogenic lines: the media-adventitia interface and the intima-media interface. Its measurement is a non-invasive, low cost and highly reproducible procedure. According to the joint ESH/ESC’s guidelines (15), the presence of subclinical carotid atherosclerosis is considered at IMT > 0.9 mm. Carotid pre-ATS is an independent marker of “multifocal” lesions in other arterial beds, with high sensitivity and specificity. Indeed an increased carotid IMT is significantly correlated to the number of coronary arteries with significant (> 50%) stenoses (16) and to a higher incidence of CAD. Therefore, detecting the presence of carotid wall lesions, even those taken early, is able to predict the occurence of future cardiovascular and cerebrovascular events (17-20).
It is possible to assert that the presence of subclinical carotid atherosclerosis together with low HDL-cholesterol concentrations points to a category of subjects at “high” CV risk.
The common denominator affecting fibrinogen levels and atherosclerosis is inflammation. Fibrinogen is a 340K dalton glycoprotein involved “early” in the formation and growth of atheroma.
Fibrinogen is also involved in a number of mechanisms with a crucial role in the “progression” of atherosclerotic lesions and it has been identified in large prospective studies as an independent risk factor for CAD (26, 27) and strong predictor for CV events ( 28, 29).
In our study, we found a significant inverse correlation between HDL-C levels and fibrinogen concentrations (p=.0302). These findings suggest a possible “synergistic” role of low HDL-C and inflammation on the atherosclerotic disease progression from subclinical lesions to clinical events. Therapeutical implications must be established in future studies. Recent studies have underlined that therapeutical modulation of markers of inflammation (such as increased levels of C-reactive protein and fibrinogen) is important in managing higher risk patients for comprehensive cerebro- and cardiovascular prevention (30, 31). Many agents (including aspirin and platelet aggregation inhibitors, lipid lowering, anti-hypertensive and antidiabetic agents, as well as antioxidants) are able to potentially reduce the levels of these markers and statins have been found particularly beneficial (32, 33).
1) Avis HJ, Vissers MN, Wijburg FA, Kastelein JJ, Hutten BA. The use of lipid-lowering drug therapy in children and adolescents. Curr Opin Investig Drugs 2009; 10: 224-31
2) Shepherd J, Cobbe SM, Ford I, et al, for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. Engl J Med 1995; 333: 1301-7.
3) Pedersen TR, Olsson AG, Faergeman O, Kjekshus J, Wedel H, Berg K, Wilhelmsen L, Haghfelt T, Thorgeirsson G, Pyörälä K, Miettinen T, Christophersen B, Tobert JA, Musliner TA, Cook TJ. Lipoprotein changes and reduction in the incidence of the major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Atherosclerosis 2004; 5 (Suppl.): 99-106
4) Ballantyne CM, Abate N, Yuan Z, King TR, Palmisano J. Dose-comparison study of the combination of Ezetimibe and simvastatin versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study. Am Heart J. 2005; 149: 464-73.
5) Cannon CP, Steinberg BA, Murphy SA, Mega JL, Braunwald E. Meta-analysis of cardiovascular outcomes trial comparing intensive versus moderate statin therapy. J Am Coll Cardiol 2006; 48: 438-45.
6) Chapman J. Beyond LDL-cholesterol reduction: the way ahead in managing dyslipidemia. Eur Heart J Suppl. 2005; 7 (Suppl F): F56–F62.
7) Kuvin JT, Rämet ME, Patel AR, et al. A novel mechanism for the beneficial vascular effects of high-density lipoprotein cholesterol: enhanced vasorelaxation and increased endothelial nitric oxide synthase expression. Am Heart J 2002; 144: 165–72.
8) Gordon DJ, Probstfield JL, Garrison RJ, et al. High density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989; 79: 8–15.
9) Prospective Studies Colloration. Blood cholesterol and vascular mortality by age, sex, and blood pressure: A meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 2007; 370: 1829–39.
10) Barter P, Gotto AM, LaRosa JC, et al. for the Treating to New Targets Investigators. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007; 357: 1301–10.
11) Grundy SM, Cleeman JI, Bairey Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ for the Coordinating Committee of the National Cholesterol Education Program, Endorsed by the National Heart, Lung, and Blood Institute, American College of Cardiology Foundation, and American Heart Association. NCEP Report Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines Circulation 2004; 110: 227-39.
12) Rydén L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, de Boer MJ, Cosentino F, Jönsson B, Laakso M, Malmberg K, Priori S, Ostergren J, Tuomilehto J, Thrainsdottir I, Vanhorebeek I, Stramba-Badiale M, Lindgren P, Qiao Q, Priori SG, Blanc JJ, Budaj A, CammJ, Dean V, Deckers J, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A,Tamargo J, Zamorano JL, Deckers JW, Bertrand M, Charbonnel B, Erdmann E, Ferrannini E, Flyvbjerg A, Gohlke H, Juanatey JR, Graham I, Monteiro PF, Parhofer K, Pyörälä K, Raz I, Schernthaner G, Volpe M, Wood D; Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC); European Association for the Study of Diabetes (EASD). Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). European Heart Journal 2007; 28: 88–136.
13) Asztalos BF, Cupples LA, Demissie S, et al. High-density lipoprotein subpopulation profile and coronary heart disease prevalence in male participants of the Framingham Offspring Study. Arterioscler Thromb Vasc Biol. 2004; 24: 2181–7
14) Asztalos BF, Collins A, Cupples LA, et al. Value of high-density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the Veterans Affairs HDL intervention trial. Arterioscler Thromb Vasc Biol. 2005; 25: 2185–91
15) Mancia G, de Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Struijker Boudier HAJ, Zanchetti A. Guidelines for the Management of Arterial Hypertension The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertension 2007; 25: 1105–87.
16) Kablak-Ziembicka A. Relationship between carotid intima-media thickness, atherosclerosis risk factors and angiography findings in patients with coronary artery disease. Acta Cardiol 2002; 57: 40 1.
17) Burke GL, Evans GW, Riley WA, Sharrett AR, Howard G, Barnes RW, Rosamond W, Crow RS, Rautaharju PM, Heiss G. Arterial wall thickness is associated with prevalent cardiovascular disease in middle-aged adults. The Atherosclerosis Risk in Communities (ARIC) Study. Stroke1995; 26: 386-91
18) Bots ML, Moons KG, Hollander M, Hoffman A, Koudstaal PJ, Grobbee DE, Breteler MM,Whitman JC, Is carotid intima-media thickness useful in cardiovascular disease risk assessment? The Rotterdam Study. Circulation 1997; 96: 1432-7.
19) O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 1999; 340: 14-22.
20) Corrado E, Rizzo M, Tantillo R, Muratori I, Bonura F, Vitale G, Novo S. Markers of inflammation and infection influence the outcome of patients with baseline asymptomaticcarotid lesions: a 5 years follow-up study. Stroke 2006; 37: 482-6.
21) Matthias W, Lorenz, Hugh S., Michiel L., Maria Rosvall and Matthias Sitzer. Prediction of clinical cardiovascular events with carotid intima-media thickness. A systematic review and meta-analysis. Circulation 2007; 115: 459-67
22) Bard RL, Kalsi H, Rubenfire MD, Brook RD. Effect of carotid atherosclerosis screening on risk stratification during primary cardiovascular disease prevention. Am J Cardiol. 2004; 93: 1030-2.
23) Bots ML, Palmer MK, Dogan S, Plantinga Y, Raichlen JS, Evans GW, O'Leary DH, Grobbee DE, Crouse Iii JR; METEOR Study Group*. Intensive lipid lowering may reduce progression of carotid atherosclerosis within 12 months of treatment: the METEOR study. J Intern Med Feb [Epub ahead of print]
24) Rizzo M, Corrado E, Coppola G, Muratori I, Novo G, Novo S. Prediction of cardio- and cerebrovascular events in patients with subclinical carotid atherosclerosis and low HDL-cholesterol Atherosclerosis 2008; 200: 389-95
25) Green D, Foiles N, Chan C, Schreiner PJ, Liu K. 2008. Elevated fibrinogen levels and subsequent subclinical atherosclerosis: the CARDIA Study. Atherosclerosis 2009; 202: 623-31
26) Wilhelmsen L, Svardsudd K, Korsan-Bengtsen K, et al. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med. 1984; 311: 501-5
27) Woodward M, Lowe GD, Rumley A, et al. Epidemiology of coagulation factors, inhibitors and activation markers: The Third Glasgow MONICA Survey. II. Relationships to cardiovascular risk factors and prevalent cardiovascular disease. Br J Haematol. 1997; 97: 785-97.
28) Maresca G., Di Blasio A., Marchioli R., Di Minno G. Measuring Plasma Fibrinogen to Predict Stroke and Myocardial Infarction. Arteriosclerosis, Thrombosis, and Vascular Biology. 1999;19: 1368-77
29) Coppola G, Corrado E, Muratori I, Tantillo R, Vitale G, Lo Coco L, Novo S. Increased levels of C-reactive protein and fibrinogen influence the risk of vascular events in patients with NIDDM. Int J Card 2006; 106: 16–20.
30) Kakafika AI, Liberopoulos EN, Mikhailidis DP. Fibrinogen: a predictor of vascular disease. Curr Pharm Des 2007; 13: 1647-59.
31) Prasad K. C-reactive protein (CRP)-lowering agents. Cardiovasc Drug Rev 2006; 24: 33-50.
32) Jialal D, Stein D, Balis D, Grundy S, Adams-Huet B, Devaraj S. Effect of Hydroxymethyl-Glutaryl-Coenzyme A Reductase Inhibitor Therapy on High Sensitive C-reactive protein Levels. Circulation 2001; 103: 1933-5.
33) Atalar E, Ozmen F, Haznedaroglu I, Acil T, Ozer N, Ovunc K, Aksoyek S, Kes S. Effects of hort-term atorvastatin treatment on global fibrinolytic capacity, and sL-selectin and sFas levels n hyperlipidemic patients with coronary artery disease. Int J Cardiol 2002; 84: 227-31. You may send an e-mail here should you wish to receive pubmed links to articles listed in reference.
*Novo S, Carità P, Corrado E, D’Ambrosi A, Novo G *Director Chair of Cardiovascular Disease, post-graduate School of Cardiology, Master of Vascular Diseases, Master of Echocardiography, Center for the Study of Preclinical Atherosclerosis and Secondary Prevention and Division of Cardiology, University Hospital “P. Giaccone”, University of Palermo.
© 2016 European Society of Cardiology. All rights reserved